Sheila Kaplan reports for STAT on a new study finding that more than half of FDA drug reviewers went on to work for the industry. “If you know a major post-employment opportunity is on the other side of the table, you give them the benefit of the doubt,” said Vinay Prasad, senior author on the paper. “You, maybe, make things a little easier on the companies.”
